^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Mycidac-C (mycobacterium indicus pranii heat-killed)

    i
    Other names: CADI-05, CADI 05
    Associations

    News

    Trials
    Company:
    Cadila
    Drug class:
    Desmocollin-3 modulator, TLR2 agonist, poly-TLR agonist
    Related drugs:
    Associations

    News

    Trials
    over2years
    TLR2 agonist as a novel therapeutic approach to treat pancreatic adenocarcinoma (AACR 2022)
    In presence of established tumor, TLR2 agonist Cadi-05 improves effector function, increases CD4+ and CD8+ expressing TIL, decreases immune suppressive TIL and retards tumor growth. Our study suggests that combination of gemcitabine and Cadi-05 inhibits the tumor growth irrespective of its size and it is coupled with increased anti-tumor response and decreased immunosuppressive function
    PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • CD4 (CD4 Molecule) • FOXP3 (Forkhead Box P3)
    |
    PD-1 expression • CD8 expression • CD4 expression • FOXP3 expression
    |
    gemcitabine • Mycidac-C (mycobacterium indicus pranii heat-killed)